Renal Dosage Adjustment Guidelines for Antimicrobials

The pharmacists will automatically adjust the doses of any of the antimicrobials included in the protocol according to the estimated creatinine clearance (generally using the Cockroft-Gault equation for patients ≥ 18 years old and the Schwartz equation for patients < 18 years old). This protocol does NOT include patients in the neonatal intensive care unit. For other pediatric patients less than 1 year of age the pharmacist must discuss the dose adjustment with the medical team who initiated the order. When a change is necessary, the pharmacist will write a new order in the Orders section of the medical record indicating the new dosage "per protocol" and enter the order in Carecast as a protocol ("P") order. No physician signature will be required to authorize the revised dosing order.

The adjustments listed in the dosing guidelines will be made unless the physician writes "Do not adjust" when ordering the antimicrobial. For vancomycin and the aminoglycosides, a pharmacokinetic consult will be performed by the pharmacist, and the ordering physician will be contacted for dosage changes unless ordered as "pharmacy to dose." If written as "pharmacy to dose" dosing will be ordered by the pharmacist.

The most current version of the Renal Dosage Adjustment Guidelines for Antimicrobials and associated antimicrobial policies can be found online at the antimicrobial stewardship program (ASP) website: www.nebraskamed.com/asp

Please note:

- If there are no clear recommendations available, the pharmacist will not perform any automatic dosage adjustment. Consult with the physician.
- Accurate estimation of creatinine clearance and glomerular filtration rate from the
 Cockroft-Gault and Schwartz equations require serum creatinine concentrations to be at
 steady-state. Acute changes in renal function (indicated by changes in urine output &
 serum creatinine) render the Cockroft-Gault and Schwartz equations unreliable as serum
 creatinine is a delayed indicator of renal function. Furthermore, CrCl calculations may be
 significantly overestimated in patients with decreased muscle mass (e.g. elderly,
 paralysis). The pharmacist should use their clinical judgment regarding these changes
 and communicate their recommendations with the team as appropriate.
- Inclusion of an agent within this guideline <u>does not</u> necessarily indicate TNMC formulary status

| Antimicrobial | Normal Dose | Renal Dosage Adjustment Based on CrCl Estimate (in ml/min)* |
|----------------|--|---|
| Abacavir (ABC) | Adult 600 mg PO q24h or 300 mg PO q12h Pediatric 8 mg/kg PO q12h | No adjustment necessary. |
| Acyclovir | Adult PO 200 mg PO 5x/day 400 mg PO 5x/day | CrCl 0-10: same dose q12h CrCl 11-25: same dose q8h CrCl 0-10: same dose q12h |
| | 800 mg PO 5x/day | CrCl 11-25: same dose q8h CrCl 0-10: same dose q12h |
| | 400 mg PO q12h | CrCl 0-10: 200 mg PO q12h |
| | /V Mucocutaneous | |

| | | T |
|------------|--|---|
| | 5 mg/kg IV q8h Immunocompromised: 6.2 mg/kg q8h | CrCl 25-50: same dose q12h CrCl 10-24: same dose q24h CrCl <10: 2.5-3.1 mg/kg IV q24h |
| | HSV encephalitis or varicella zoster virus 10 mg/kg IV q8h Immunocompromised: 12.4 mg/kg IV q8h | CrCl 25-50: same dose q12h CrCl 10-24: same dose q24h CrCl <10: 5-6.2 mg/kg IV q24h |
| | | HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: dose as CrCl <10 CVVH: See dosing at end of this document |
| | Pediatric PO | |
| | 6.25-20 mg/kg PO q6h | CrCl 10-25: same dose q8h CrCl <10: same dose q12h |
| | 15-20 mg/kg IV q8h | CrCl 25-50: same dose q12h CrCl 10-24: same dose q24h CrCl <10: 50% IV q24h ^T |
| | | HD/CAPD: No data. |
| Amantadine | Adult 100 mg PO q12h or 200 mg daily | CrCl 30-50: Administer 200 mg on day 1, then 100 mg/day |
| | | CrCl 15-29: Administer 200 mg on day 1, then 100 mg on alternate days |
| | | CrCl <15: Administer 200 mg every 7 days |
| | | HD: Administer 200 mg every 7 days CAPD: No supplemental dose is needed. |
| | Pediatric 1-9 years: 5 mg/kg/day PO in 2 divided doses (maximum dose: 150 mg/day) | No clear recommendations. |
| | ≥10 years and < 40 kg: 5 mg/kg/day PO in 2 divided doses (maximum dose: 150 mg/day) | |
| | ≥10 years and ≥40 kg: 100 mg PO q12h | |
| Amikacin | Adult Extended interval dosing (most indications*): 15 mg/kg once daily adjusted by serum level 6-14 hrs after start of infusion and Hartford | Extended interval dosing frequency determined by levels/Hartford nomogram |
| | nomogram (see PK training packet on ASP website [§]) | |

| 10 mg/kg/day may be used for UTIs | |
|---|--|
| Traditional dosing 5 mg/kg IV q8h | Traditional dosing (empiric, before levels): |
| Monitoring of serum levels is recommended. | CrCl 51-90: 60-90% IV q12h [†] CrCl 10-50: 30-70% IV q12-18h [‡] |
| *Refer to TNMC PK training packet on ASP website§ for exclusions to extended-interval | CrCl <10: 20-30% IV q24-48h [‡] |
| dosing | HD/CAPD: Dose according to levels. CVVH: See dosing at end of this |
| Pediatric Traditional dosing 5 mg/kg IV q8h | document |
| Adult 250-1000 mg PO q8h | Same for Adult & Pediatric CrCl 10-30: same dose q12h CrCl <10: same dose q24h |
| Pediatric 12.5-25 mg/kg PO g8-12h | HD: Dose daily as CrCl <10. Give |
| (25-90 mg/kg/day) | after dialysis on dialysis days. CAPD: 250 mg PO q12h |
| | |
| <u>Adult</u> 500/125 mg PO q8h | CrCl 10-30: 250/125 mg PO q12h CrCl <10: 250/125 mg PO q24h |
| 875/125 mg PO q12h | CrCl 10-30: 500/125 mg PO q12h CrCl <10: 500/125 mg PO q24h |
| 1000/62.5 mg PO q12h (XR formulation) | XR formulation NOT recommended with CrCl < 30. |
| | HD: Dose as daily CrCl <10. Give after dialysis on dialysis days. CAPD: 250/62.5 mg PO q12h |
| Pediatric 15-45 mg (amoxicillin component)/kg 12h AOM: 22.5-45 mg/kg q12h [30-90 mg (amoxicillin component)/kg/day] | CrCl 10-30: same dose q12h CrCl <10: same dose q24h |
| | HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: No clear recommendations. |
| Adult & Pediatric 0.7-1 mg/kg IV q24h | No adjustment necessary |
| Adult & Pediatric | |
| 3 mg/kg IV q24h | No adjustment necessary |
| (Automatic dose substitution to 3 mg/kg, refer to policy on ASP website $^{\$}$) | |
| Adult | 200 |
| PO 250-1000 mg PO q6h | PO CrCl <10: same dose q12h |
| | Traditional dosing 5 mg/kg IV q8h Monitoring of serum levels is recommended. *Refer to TNMC PK training packet on ASP website for exclusions to extended-interval dosing Pediatric Traditional dosing 5 mg/kg IV q8h Adult 250-1000 mg PO q8h Pediatric 12.5-25 mg/kg PO q8-12h (25-90 mg/kg/day) AOM: 90 mg/kg/day PO divided q8-12h Adult 500/125 mg PO q12h 1000/62.5 mg PO q12h (XR formulation) Pediatric 15-45 mg (amoxicillin component)/kg 12h AOM: 22.5-45 mg/kg q12h [30-90 mg (amoxicillin component)/kg/day] Adult & Pediatric 0.7-1 mg/kg IV q24h Adult & Pediatric 3 mg/kg IV q24h (Automatic dose substitution to 3 mg/kg, refer to policy on ASP website for the policy on the poli |

| | <i>IV</i> 1-2 g IV q4-6h | IV CrCl 30-50: same dose q8h CrCl <30: same dose q12h HD: Dose as CrCl <10. Give after dialysis on dialysis days. CAPD: 250 mg PO/IV q12h |
|---|---|---|
| | D. W. d. | |
| | Pediatric PO | PO/IV |
| | 12.5-25 mg/kg PO q6h | CrCl <10: same dose q12h |
| | IV 25-100 mg/kg IV q6h | HD: Dose as CrCl <10. Give after dialysis on dialysis days. CAPD: No clear recommendations. |
| Ampicillin/sulbactam | Adult | |
| | 1.5-3 g IV q6h | CrCl 30-50: same dose q8h CrCl 15-29: same dose q12h CrCl <15: same dose q24h |
| | | HD: Dose daily as CrCl <15. Give after dialysis on dialysis days. CAPD: Dose as CrCl <15. |
| | Pediatric 25-100 mg (ampicillin component)/kg IV q6h | CrCl 15-29: same dose q12h CrCl <15: same dose q24h |
| | | HD: Dose as daily CrCl <15. Give after dialysis on dialysis days. CAPD: Dose as CrCl <15. |
| Atazanavir (ATV) | Naïve Adult | No repoladiustment pessenti |
| RTV=ritonavir | ATV + RTV 300/100mg daily w/food | No renal adjustment necessary. |
| PPI: proton pump inhibitor H2RA: histamine 2 receptor antagonist EFV: efavirenz TDF:tenofovir | Unable to tolerate RTV and/or on H2RA: ATV 400mg daily w/food With TDF, H2RA or PPI: ATV + RTV | PPI contraindicated in treatment experienced patients (package labeling) due to decrease in AUC by 75%. In naïve patients PPI should not exceed 20 mg omeprazole/day or |
| AUC: area under the curve | 300/100mg daily w/food | equivalent. PPI should be given 12 |
| | With EFV: ATV+RTV: 400/100mg daily w/food | hours prior to ATV. H2RA dose should not exceed equivalent of famotidine 20 mg q12h. |
| | Pediatric ≥6yr: 15-24kg; ATV+RTV 150/80mg daily; 25-31kg: 200/100mg daily; 32-38kg 250/100mg daily; ≥39kg 300/100mg daily | ATV/RTV should be administered simultaneously with or 10 hours after H2RA |
| | w/food | ATV 400 mg once daily should be |
| | ≥13yr, ≥39kg and unable to tolerate RTV: ATV 400mg daily w/food | administered at least 2 hours before and at least 10 hours after the H2RA |
| | Experienced | |

| | Adult On H2RA: ATV + RTV 300/100mg daily w/food | |
|--------------|--|--|
| | With TFV and H2RA: ATV+RTV 400/100mg daily w/food NOTE : PPI and EFV are contraindicated in treatment-experienced patients receiving atazanavir | |
| | Pediatric ≥6yr: 25-31kg: ATV+RTV 200/100mg daily; 32-38Kg: 250/100mg daily; ≥39kg 300/100mg daily w/food | |
| Atovaquone | Adult & Pediatric (>13yo) 1500 mg PO divided q12-24h Pediatric 20 mg/kg PO q12h | No data. |
| Azithromycin | Adult 250-500 mg PO/IV q24h | No adjustment necessary. |
| | Pediatric 5-10 mg/kg PO q24h | Caution advised if CrCl < 10 (AUC increased by 35%). |
| Aztreonam | Adult 1 g IV q8h | CrCl 10-30: same dose IV q12h CrCl <10: same dose IV q24h |
| | Anti-pseudomonal/moderate-severe infection: 2 gm IV q8hr | HD: Dose daily as for CrCl <10 and administer after dialysis on dialysis days. CAPD: Dose as CrCl <10. CVVH: See dosing at end of this document |
| | Pediatric 30-60 mg/kg IV q6-8h | CrCl 10-30: 50% IV at same interval [‡] CrCl <10: 25% IV at same interval [‡] HD: Dose as for CrCl <10 with an extra 3.25-7.5 mg/kg IV after dialysis. |
| | | CAPD: Dose as CrCl <10. |
| Cefazolin | Adult 2 g IV q8h (All Gram-negative infections, S. aureus bloodstream infections, moderatesevere infections, patients >80kg) | CrCl 10-30: same dose q12h CrCl <10: 1-2 g q24h |
| | 1 g IV q8h (surgical prophylaxis for patients <80kg, simple urinary tract infections) | HD: 1 gm IV q24hr, administered after HD -OR- 2 gm (~20 mg/kg) IV after each HD three times weekly CAPD: 500 mg IV q12h CVVH: See dosing at end of this document |
| | Pediatric 16.7-50mg/kg IV q8h | CrCl 10-30: same dose q12h CrCl <10: same dose q24h |

| | | HD: 2.5-7.5 mg/kg IV given only after dialysis. CAPD: No adjustment necessary. |
|--|---|---|
| Cefepime Refer to dosing protocol on ASP website§ | Adult 1 g IV q6h | CrCl 30-50: 1 g IV q8h CrCl 10-29: 1 g IV q12h CrCl <10: 1 g IV q24h CVVH: See dosing at end of this document |
| | Febrile Neutropenia: 2 g IV q8hr | CrCl 30-50: 2 g IV q12h CrCl 10-29: 1 g IV q12h CrCl <10: 1 g IV q24h CVVH: See dosing at end of this document |
| | Mild-moderate UTI or community-acquired pneumonia not caused by <i>P. aeruginosa</i> : 1 g IV q12hr | CrCl 10-50: 1 g IV q24h CrCl <10: 500 mg IV q24h |
| | | HD: Dose daily as CrCl <10. Administer after dialysis on dialysis days. CAPD: Dose for CrCl <10. |
| | Pediatric Pediatric ≥ 40 kg: see adult dose Pediatric <40 kg: | CrCl 10-50: same dose q12 (for q8h dosing)-q24h (for q12h dosing) CrCl <10: 50% q24h [‡] |
| | 50 mg/kg IV q8-12h | HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: 50 mg/kg IV q48h |
| Cefotaxime | Adult 1-2 g IV q8h (Therapeutic interchange to ceftriaxone in adults, see cephalosporin therapeutic interchange policy) | CrCl 10-50: same dose q12h CrCl <10: same dose q24h HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: 1 g IV q24h |
| | Pediatric 25-100mg/kg IV q6-8h (100-200mg/kg/day) | CrCl <20: same dose q24h HD: Dose daily as CrCl <20. Give after dialysis on dialysis days. CAPD: 50-100 mg/kg IV q24h |
| Cefoxitin | Adult 1-2 g IV q8h For coverage of Enterobacteriaceae (E. coli, | CrCl 10-30: same dose q12h CrCl <10: same dose IV q24h |
| | Klebsiella sp. Proteus sp. etc.): 2 g IV q6h | HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: 1 g IV q24h |

| | Pediatric 20-40mg/kg IV q6h | CrCl 51-90: same dose q8h CrCl 10-50: same dose q12h CrCl <10: same dose q24-48h HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: No clear recommendations. |
|-------------|--|---|
| Ceftazidime | Adult 1 g IV q8h Anti-pseudomonal dosing: 2 gm IV q8hr | CrCl 10-30: same dose q12h CrCl <10: 1 gm q24h HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: 1 g IV x1, then 500 mg IV q24h CVVH: See dosing at end of this document |
| | Pediatric 30-50 mg/kg IV q8h | CrCl 30-50: same dose q12h CrCl 10-29: same dose q24h CrCl <10: same dose q48h HD: Dose as CrCl <10. Give after dialysis on dialysis days. CAPD: 30-75 mg/kg IV x1, then 50% q24h [‡] |
| Ceftriaxone | Adult 1 g IV q24h Patients >80 kg: | No adjustment necessary. CAPD: 1 g IV q12h |
| | 2 g IV q24h Meningitis: 2 g IV q12h Pediatric 25-100mg/kg IV q12-24h (50-100mg/kg/day) | No adjustment necessary. |
| Cefuroxime | Adult PO 250-500 mg PO q12h | No adjustment necessary. |
| | /V 1.5 g IV q8h | CrCl 10-20: 1.5 gm IV q12h CrCl <10: 1.5 gm q24h HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: Dose as CrCl <10. |

| | | No adjusting out to a series |
|-----------------|---|---|
| | Pediatric Pediatric | No adjustment necessary. |
| | PO Cefuroxime 10-15 mg/kg PO q12h | HD: Give after dialysis on dialysis days. |
| | /V 25-50mg/kg IV q8h | CrCl 10-20: same dose q12h CrCl <10: same dose q24h |
| | 25 55mg/kg IV qon | HD: Dose daily as CrCl <10. Give after dialysis on dialysis days. CAPD: Dose as CrCl <10. |
| Cephalexin | Adult 250 - 1000 mg PO q6h | CrCl 50-90: same dose PO q8h CrCl <50: same dose PO q12h |
| | | HD: Dose as CrCl <50. Give after dialysis on dialysis days. CAPD: Dose as CrCl <50. |
| | Pediatric | |
| | 6.25-37.5 mg/kg PO q6h | CrCl 10-40: same dose q8h CrCl <10: same dose q12h |
| | | HD: Dose as CrCl <10. Give after dialysis on dialysis days. CAPD: Dose as CrCl <10. |
| Chloramphenicol | Adult 12.5-25 mg/kg IV q6h | No adjustment necessary. |
| | Pediatric 6.25-25 mg/kg IV q6h | |
| Ciprofloxacin | Adult | |
| | PO 250-750 mg PO q12h (consider 750mg q8h for pneumonia/severe infection) | CrCl <30: same dose q24h |
| | | HD/CAPD: Dose as CrCl <30 given after dialysis. |
| | /V 400 mg IV q8-12h (q8h for pneumonia/severe infection) | CrCl <30: same dose q12 (for q8h regimen)-24h (for q12h regimen) |
| | | HD/CAPD: Dose as CrCl <30 given after dialysis. |
| | Pediatric PO | |
| | 10-20 mg/kg PO q12h | No clear recommendations. |
| | 10-15 mg/kg IV q8-12h | |
| Clarithromycin | Adult 0.5 – 1 g PO q12h | Same for Adult & Pediatric CrCl <30: 50% PO q12h [‡] |
| | Pediatric 7.5 mg/kg PO q12h | HD: Dose as CrCl <30. Give after dialysis on dialysis days. |

| | | CAPD: No adjustment necessary. |
|---|---|--|
| Clindamycin | Adult | |
| | <i>PO</i> 150-450 mg PO q6-8h | |
| | 130-430 mg FO 40-6m | |
| | IV | |
| | Standard dose: 600 mg IV q8h | |
| | No confident for eliferation and the old | |
| | Necrotizing fasciitis: 900 mg IV q8h | No adjustment necessary. |
| | | No adjustment necessary. |
| | D. Park | |
| | Pediatric PO | |
| | 2.5-10 mg/kg PO q6-8h | |
| | (10-30 mg/kg/day) | |
| | | |
| | /V 6.25-10 mg/kg IV q6-8h | |
| | (25-40 mg/kg/day) | |
| Colistin base IV | Adult | Use loading dose in renal dysfunction: |
| | 5 mg/kg/day (lesser of actual or ideal body | Loading dose: 2.5 mg/kg IV q12h x2 |
| Restricted to ID service or | weight) colistin base IV divided in 2-3 doses | doses. Maintenance dosing begins |
| pulmonary service consultation | | 24 hours after first loading dose |
| | | CrCl >40: no adjustment needed |
| | | CrCl 20-40: 75% IV q12h ₊ [‡] |
| | | CrCl 10-19: 50% IV q12h [†] |
| | | CrCl <10, HD/CAPD: 50 mg IV q12h (after HD on HD days) |
| | | SLED: While on SLED dose as |
| | | CrCl>40 |
| | | While off SLED dose as CrCl<10 |
| | | Soc collectin decing and restriction |
| | | See colistin dosing and restriction document available on ASP website§ |
| Colistin base Inhaled | Adult | No adjustment necessary |
| 5 | 75-150 mg inhaled q12h | |
| Restricted to ID service or | Dodiatria | See colistin dosing and restriction document available on ASP website§ |
| pulmonary service consultation | Pediatric 30-75 mg inhaled q12h | document available on ASP website |
| Dapsone | Adult | |
| 2 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 | 50-100 mg PO q24h | |
| | | No clear guidelines, but adjustment |
| | Pediatric | recommended. |
| Daptomycin | 1-2 mg/kg PO q24h Adult | |
| Daptomyoni | 6 mg/kg IV q24h | CrCl <30: same dose IV q48h |
| Restricted to ID Service review | | · |
| and approval for non FDA- | UTI or skin/skin structure infection: 4 mg/kg | HD: Dose as CrCl <30. Give after |
| approved indications | IV q24h | dialysis on dialysis days. CAPD: Dose as CrCl <30. |
| | Safety and efficacy not established in | OALD. DOGG AS CICI COU. |
| | pediatrics. | |
| Darunavir (DRV) | <u>Naïve</u> | |
| | Adult | |
| | DRV+RTV 800/100mg daily w/food | |

| | | 1 |
|-------------------------------------|---|--|
| | Pediatric ≥6yrs; 20-29kg: DRV+RTV 375/50mg Q12H; 30-39Kg 450/60mg Q12H; ≥40kg 600/100mg Q12H Experienced Adult DRV+RTV 600/100mg Q12H w/food | No adjustment necessary. |
| | Pediatric | |
| Dicloxacillin | No recommendations. | |
| DICIOXACIIIII | Adult 250-500 mg PO q6h Pediatric 6.25-12.5 mg/kg PO q6h | No adjustment necessary. |
| Didanosine (enteric coated, DDI EC) | Adult ≥60kg 400 mg EC PO q24h if given with TDF: 250 mg PO q24h <60 kg: 250 mg EC PO q24h if given with TDF: 200 mg PO q24h | CrCl 30-59 & ≥60kg: 200 mg EC q24h CrCl 30-59 & <60kg: 125 mg EC q24h CrCl 10-29: 125 mg PO EC q24h CrCl <10, HD/CAPD: Dose as CrCl 10-29 and if patient is <60kg use oral solution instead of EC formulation |
| | Pediatric 100-120 mg/m ² PO q12h | No clear recommendations except for HD. HD: 25% of total dose PO q24h [∓] |
| Doxycycline | Adult 100 mg PO/IV q12h Pediatric *not to be used in children < 8yo 1-4 mg/kg PO/IV q12-24h (2-4 mg/kg/day) | No adjustment necessary. |
| Efavirenz (EFV) | Adult 600 mg PO QHS (avoid food) Pediatric 200-600 mg PO q24h | No adjustment necessary. |
| Emtricitabine (FTC) | Adult: Capsule: 200 mg once daily Solution: 240 mg once daily | CrCl 30-49: Capsule: 200mg q48h; Solution: 120 mg q24h CrCl 15-29: Capsule: 200 mg q72h; Solution: 80 mg q24h CrCl <15: Capsule: 200 mg q96h; Solution: 60 mg q24h HD: Dose as CrCl <15. Give after |
| | Pediatric 0-3 months: Solution: 3 mg/kg/day 3 months to 17 years: Capsule: Children >33 kg: 200 mg once | dialysis on dialysis days. No clear recommendations |

| | 1 | 1 |
|----------------------------|---|---|
| | daily | |
| | Solution: 6 mg/kg once daily; maximum: 240 | |
| | mg/day | |
| Ertapenem | Adult | |
| | 1 g IV q24h | CrCl < 30: 500 mg IV q24h |
| | | HD/CAPD: Dose as CrCl < 30 given after dialysis on dialysis days. |
| | | |
| | Pediatric Pediatric | |
| | 15 mg/kg IV q12h | No clear recommendations. |
| Erythromycin | Adult | Same for Adult & Pediatric |
| | PO | 0.01.40.500/.00/.01 |
| | 250-500 mg PO q6-12h | CrCl <10: 50% PO/IV at same interval. |
| | IV | HD/CARD: Doop on CrCL 410 |
| | 15-20 mg/kg/day IV divided q6-8h | HD/CAPD: Dose as CrCl <10. |
| | Pediatric PO | |
| | 7.5-16.7 mg/kg PO q6-8h | |
| | (30-50 mg/kg/day) | |
| | IV . | |
| | 3.75-12.5 mg/kg IV q6h | |
| Erythromycin/sulfisoxazole | Adult 400 mg (erythromycin component) PO q6h | |
| | Pediatric 10-16.7 mg (erythromycin component)/kg PO | No clear recommendations. |
| | q6-8h | |
| | [40-50 mg (erythromycin component)/kg/day] | |
| Ethambutol | Adult 15-25 mg/kg PO q24h (max. dose 2.5 grams) | Same for Adult & Pediatric CrCl 10-50: same dose PO q24-36h CrCl <10: same dose PO q48h |
| | Pediatric | HD: Give dose only after dialysis. |
| | 15-25 mg/kg PO q24h (max. dose 2.5 grams) | CAPD: Dose as CrCl <10. |
| | | |
| Etravirine (ETV) | 200 mg PO q12h with food | No adjustment necessary |
| Famciclovir | Adult | |
| | 500 mg PO q8h (varicella zoster virus) | CrCl 40-59: same dose q12h CrCl 20-39: same dose q24h |
| | | CrCl <20: 50% q24h ⁺ |
| | Safety and efficacy not established in | IID. 500/ often and district and T |
| | pediatrics. | HD: 50% after each dialysis session. *CAPD: No clear recommendations. |
| Fluconazole | Adult | Invasive candidiasis: |
| | Invasive candidiasis (susceptible C. albicans, | CrCl <30: 800 mg (12mg/kg) load |
| | C. tropicalis, C. parapsilosis): | x1dose then 50% (3 mg/kg) PO/IV |
| | 800 mg (12 mg/kg) load x1dose then 400 mg | q24h [‡] |
| | (6 mg/kg) PO/IV q24h | LID: 000 mag (40 mag (//>) 4 - |
| | | HD: 800 mg (12mg/kg) load x1dose |

| | | then 400 mg (6 mg/kg) PO/IV after HD three times weekly CAPD: 800 mg (12mg/kg) load x1dose then 50% (3 mg/kg) PO/IV q24h [‡] CVVH: See dosing at end of this document |
|---|---|--|
| | Esophageal candidiasis: 200 mg PO/IV q24h Oropharyngeal candidiasis: 100 mg q24h | Esophageal/Oropharyngeal candidiasis: CrCl <30: 50% PO/IV q24h [‡] |
| | | HD: 100% PO/IV after each dialysis [‡] CAPD: 50% PO/IV q24h [‡] |
| | Pediatric 3-12 mg/kg/day PO/IV q24h | CrCl 20-50: 50% PO/IV q24h [‡] CrCl <20: 25% PO/IV q24h [‡] HD: Give dose only after dialysis. CAPD: 25% PO/IV q24h [‡] |
| Flucytosine | Adult 50-150 mg/kg/day PO divided q6h | CrCl 10-50: same dose q12-24h CrCl <10: same dose q24h HD/CAPD: Give dose only after dialysis. |
| | Pediatric 25-37.5 mg/kg PO q6h | CrCl 20-40: same dose q12 CrCl 10-19: same dose q24h CrCl <10: same dose q48h HD/CAPD: Give dose only after dialysis. |
| Fosamprenavir (FPV) RTV = ritonavir EFV=efavirenz | ARV Naïve Adult FPV 1400mg q12h OR 1400mg + RTV 200mg daily OR 1400mg + RTV 100mg daily OR 700mg+ RTV 100mg q12h With EFV or NVP: 1400mg + RTV 300mg daily | |
| | Pediatric 2-5yr: 30mg/kg q12h ≥6yr: 30mg/kg q12h OR FPV 18mg/kg+ RTV 3mg/kg q12h; (maximum dose: FPV 1400mg or RTV 200mg/day) | No adjustment necessary. |
| | ARV Experienced Adult FPV 700mg + RTV 100mg q12h Pediatric | |
| | ≥6yr: FPV 18mg/kg + RTV 3mg/kg q12h (maximum dose: 1400mg+RTV 200mg/day) | |
| Foscarnet | Adult Mucocutaneous HSV: 40 mg/kg IV q8h | CrCl as ml/min/kg body weight CrCl >1.0-1.4: 30 mg/kg IV q8h CrCl >0.8-1.0: 35 mg/kg IV q12h CrCl >0.6-0.8: 25 mg/kg IV q12h |

<u>Disseminated CMV, induction:</u> 60 mg/kg IV q8h

CrCl >1.0-1.4: 45 mg/kg IV q8h CrCl >0.8-1.0: 50 mg/kg IV q12h CrCl >0.6-0.8: 40 mg/kg IV q12h CrCl >0.5-0.6: 60 mg/kg IV q24h CrCl 0.4-0.5: 50 mg/kg IV q24h CrCl <0.4: Not recommended.

CrCl >0.5-0.6: 40 mg/kg IV q24h CrCl 0.4-0.5: 35 mg/kg IV q24h CrCl <0.4: Not recommended.

<u>Disseminated CMV, maintenance:</u> 90-120 mg/kg IV q24h

CrCl >1.0-1.4: 70-90 mg/kg IV q24h CrCl >0.8-1.0: 50-65 mg/kg IV q24h CrCl >0.6-0.8: 80-105 mg/kg IV q48h CrCl >0.5-0.6: 60-80 mg/kg IV q48h CrCl 0.4-0.5: 50-65 mg/kg IV q48h CrCl <0.4: Not recommended.

HD: 40-60 mg/kg IV after each dialysis session.

Pediatric

Induction 60 mg/kg IV q8h

CrCl as ml/min/kg body weight

Induction

CrCl ≥ 1.6: 60 mg/kg/8h CrCl 1.5: 56.5 mg/kg/8h CrCl 1.4: 53 mg/kg/8h CrCl 1.3: 49.4 mg/kg/8h CrCl 1.2: 45.9 mg/kg/8h CrCl 1.1: 42.4 mg/kg/8h CrCl 1: 38.9 mg/kg/8h CrCl 0.9: 35.3 mg/kg/8h CrCl 0.8: 31.8 mg/kg/8h CrCl 0.7: 28.3 mg/kg/8h CrCl 0.6: 24.8 mg/kg/8h CrCl 0.5: 21.2 mg/kg/8h

CrCl 0.4: 17.7 mg/kg/8h

Maintenance

90-120 mg/kg IV q24h

40-60 mg/kg IV q12h

Maintenance

CrCl 1-1.4: 70-90 mg/kg IV q24h CrCl 0.8-<1: 50-65 mg/kg IV q24h CrCl 0.6-<0.8: 80-105 mg/kg IV q48h CrCl 0.5-<0.6: 60-80 mg/kg IV q48h CrCl 0.4-<0.5: 50-65 IV q48h CrCl < 0.4: not recommended

HD/CAPD: No data.

| Adult Uncomplicated cystitis: 3g oral x 1 dose CrCl <50: same dose |
|--|
| Susceptibility testing required for use other than a one time dose for uncomplicated cystitis ID Service consultation strongly recommended for use other than uncomplicated cystitis: Pediatric ≥15 yrs: SEE ADULT DOSE ID Service consultation strongly recommended for use other than uncomplicated cystitis: Pediatric ≥15 yrs: SEE ADULT DOSE Pediatric ≥14 yrs: Uncomplicated cystitis: 2g oral x 1 dose Complicated cystitis: 2g oral every 2 days Refer to fosfomycin information on ASP website Pediatric ≤14 yrs: Uncomplicated cystitis: 2g oral every 2 days Pediatric ≤1 yr: Uncomplicated cystitis: 1g oral x 1 dose Complicated and CrCl<50: Age ≤14 yrs: 2g oral every 3 days Age ≤1 yr: 1g oral every 3 days CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week |
| Susceptibility testing required for use other than a one time dose for uncomplicated cystitis ID Service consultation strongly recommended for use other than uncomplicated cystitis: Refer to fosfomycin information on ASP website [§] Ganciclovir Pediatric ≥15 yrs: SEE ADULT DOSE Pediatric ≥14 yrs: Uncomplicated cystitis: 2g oral x 1 dose Complicated cystitis: 2g oral every 2 days Pediatric ≤14 yrs: Uncomplicated cystitis: 2g oral every 2 days Pediatric ≤1 yr: Uncomplicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral every 2 days Ganciclovir Adult PO 1 g PO q8h CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl 10-24: 500 mg PO q3x/week |
| Susceptibility testing required for use other than a one time dose for uncomplicated cystitis ID Service consultation strongly recommended for use other than uncomplicated cystitis: Refer to fosfomycin information on ASP website [§] Ganciclovir Pediatric ≥15 yrs: SEE ADULT DOSE Pediatric ≥14 yrs: Uncomplicated cystitis: 2g oral x 1 dose Complicated cystitis: 2g oral every 2 days Pediatric ≤14 yrs: Uncomplicated cystitis: 2g oral every 2 days Pediatric ≤1 yr: Uncomplicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral every 2 days Ganciclovir Adult PO 1 g PO q8h CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl 10-24: 500 mg PO q3x/week |
| dose for uncomplicated cystitis ID Service consultation strongly recommended for use other than uncomplicated cystitis: Refer to fosfomycin information on ASP website Ganciclovir Pediatric ≥15 yrs: SEE ADULT DOSE Pediatric ≥14 yrs: Uncomplicated cystitis: 2g oral x 1 dose Complicated cystitis: 2g oral every 2 days Pediatric ≤14 yrs: Uncomplicated cystitis: 2g oral every 2 days Pediatric ≤14 yrs: Uncomplicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral every 2 days Ganciclovir Adult PO 1 g PO q8h CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week |
| Pediatric ≥15 yrs: SEE ADULT DOSE SEE ADULT DOSAGE |
| ID Service consultation strongly recommended for use other than uncomplicated cystitis: Refer to fosfomycin information on ASP website [§] Ganciclovir Pediatric ≤14 yrs: Uncomplicated cystitis: 2g oral every 2 days Pediatric ≤1 yr: Uncomplicated cystitis: 2g oral every 2 days Pediatric ≤1 yr: Uncomplicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral every 2 days CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl 10-24: 500 mg PO 3x/week |
| strongly recommended for use other than uncomplicated cystitis: Refer to fosfomycin information on ASP website Ganciclovir Pediatric ≤14 yrs: Uncomplicated cystitis: 2g oral every 2 days Pediatric ≤1 yr: Uncomplicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral every 2 days Ganciclovir Adult PO |
| other than uncomplicated cystitis: 2g oral x 1 dose Complicated cystitis: 2g oral every 2 days Refer to fosfomycin information on ASP website [§] Ganciclovir Ganciclovir Adult PO 1 g PO q8h If complicated and CrCl<50: Age ≤14 yrs: 2g oral every 3 days CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week |
| Complicated cystitis: 2g oral every 2 days Refer to fosfomycin information on ASP website [§] Pediatric ≤1 yr: Uncomplicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral every 2 days Ganciclovir Adult PO 1 g PO q8h CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week |
| Refer to fosfomycin information on ASP website [§] Pediatric ≤1 yr: Uncomplicated cystitis: 1g oral x 1 dose Complicated cystitis: 1g oral every 2 days Ganciclovir Adult PO 1 g PO q8h CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week // Induction: |
| Refer to fosfomycin information on ASP website Pediatric ≤1 yr: |
| Complicated cystitis: 1g oral every 2 days Adult PO |
| Adult |
| PO 1 g PO q8h CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week IV Induction: |
| 1 g PO q8h CrCl 50-69: 1.5 g PO q24h or 500 mg PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl 10: 500 mg PO 3x/week // Induction: |
| PO q8h CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week // Induction: |
| CrCl 25-49: 1 g PO q24h CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week // Induction: |
| CrCl 10-24: 500 mg PO q24h CrCl <10: 500 mg PO 3x/week // Induction: |
| //V Induction: |
| Induction: |
| |
| 1 |
| 5 mg/kg IV q12h |
| CrCl 10-24: 1.25 mg/kg IV q24h |
| CrCl <10:1.25 mg/kg IV 3x/week |
| |
| |
| Maintenance |
| 5 mg/kg IV q24h |
| CrCl 25-49: 1.25 mg/kg IV q24h |
| CrCl 10-24: 0.625 mg/kg IV q24h CrCl <10: 0.625 mg/kg IV 3x/week |
| CICI < 10. 0.025 Hig/kg IV 5X/Week |
| HD (PO/IV): Dose as CrCl <10 given |
| after dialysis sessions. |
| |
| Pediatric Po |
| PO |
| 30 mg/kg PO q8h No clear recommendations. |
| l /V |
| Induction: CrCl 50-69: 2.5 mg/kg IV q12h |
| 5 mg/kg IV q12h CrCl 25-49: 2.5 mg/kg IV q24h |
| CrCl 10-24: 1.25 mg/kg IV q24h |
| CrCl <10:1.25 mg/kg IV 3x/week |
| Maintenance: |
| 5 mg/kg IV q24h |
| CrCl 10-24: 0.625 mg/kg IV q24h |
| CrCl <10: 0.625 mg/kg IV 3x/week |
| 5.5. 3.5. 5.525g/ng 17 6/7 Wook |
| HD (PO/IV): Dose as CrCl <10 given |
| after dialysis sessions. |

| Gentamicin | Adult Extended interval dosing (most indications*): 7 mg/kg once daily • adjusted by serum level 6-14 hrs after start of infusion and Hartford nomogram (see PK training packet on ASP website§) 5 mg/kg/day may be used for UTIs | Extended interval dosing frequency determined by levels/Hartford nomogram |
|--------------|---|---|
| | Traditional dosing 1.5-2.5 mg/kg IV q8h Monitoring of serum levels is recommended. *Refer to TNMC PK training packet on ASP website [§] for exclusions to extended-interval dosing Pediatric | Traditional dosing (empiric, before levels): CrCl 51-90: 60-90% IV q8-12h [‡] CrCl 10-50: 30-70% IV q12h [‡] CrCl <10: 20-30% IV q24-48h [‡] HD/CAPD: Dose according to levels. CVVH: See dosing at end of this document |
| Imipenem | Traditional dosing 1.5-2.5 mg/kg IV q8h Adult 500 mg IV q6h | Adjusted by weight and CrCl. See Micromedex for adjustment. |
| | For any other adult doses, use adjustment tables provided by Micromedex. | HD: Dose as CrCl <20. Dose after dialysis on dialysis days. CAPD: Dose as CrCl <10 |
| | Pediatric 15-25 mg/kg IV q6h | CrCl 41-70: 50% IV q6h [‡] CrCl 21-40: 35% IV q8h [‡] CrCl 6-20: 25% IV q12h [‡] HD: Same dose q12h, given after |
| | | dialysis on dialysis days. CAPD: Dose as CrCl 6-20 |
| Indinavir | Adult 800 mg PO q8h | No adjustment necessary. |
| | Pediatric: 500 mg/m ² PO q8h | No clear recommendations (<20% renal elimination). |
| Isoniazid | Adult 5 mg/kg PO q24h (max dose 300 mg daily) | No adjustment necessary. |
| | Pediatric 10-15 mg/kg PO q24h (max dose 300 mg daily) | HD/CAPD: Give dose after dialysis on dialysis days. |
| Itraconazole | Adult 100-200 mg PO q12h | No renal adjustment necessary. |
| | Endemic fungi (Histoplasmata sp. Coccidioides sp. Blastomycetes sp.): 200 mg PO q8h x2days load then 200 mg PO q12h | Avoid concomitant proton pump inhibitors or histamine receptor antagonists |
| | <u>Pediatric</u> | Suspension should be administered on an empty stomach |

| | 3-5 mg/kg PO q24h | |
|-----------------------------|--|---|
| | 3-3 mg/kg r O q24m | Capsules should be administered with meal or acidic beverage |
| | | Therapeutic drug monitoring should be considered. Goal steady-state trough obtained after 5-7 days of therapy for active disease >1mg/dL (sum of hyrdoxy-itraconazole and itraconazole) |
| Lamivudine (3TC) | Adult 150 mg q12h OR 300 mg PO q24h | CrCl 30-49: 150 mg PO q24h CrCl 15-29: 150 mg PO x1, then 100 mg PO q24h CrCl 5-14: 150 mg PO x1, then 50 mg PO q24h CrCl <5: 50 mg PO x1, then 25 mg PO q24h (Note: because lamivudine is well-tolerated and available in 100 mg tablets, some practitioners will prescribe 50 mg PO daily (half of a 100 mg tablet) |
| | | HD/CAPD: Dose as CrCl <5. |
| | Pediatric 2-4 mg/kg PO q12h | No clear recommendations (70% renal elimination). |
| Levofloxacin | Adult 750 mg q24h | CrCl 20-49: 750 mg q48h CrCl <20 or HD/PD: 750 mg x1 dose then 500 mg q48h |
| | 500 mg q24h | CrCl 20-49 ml/min: 500 mg x 1, then 250mg Q24h CrCl <20 ml/min, HD/PD: 500mg X 1, then 250mg Q48h |
| | Urinary tract infection: 250 mg q24h | CrCl ≤20: 250 mg q48h (except when ordered duration ≤3 days, then no dose adjustment needed), HD/PD: no information available |
| | Pediatric < 6 months: use not recommended ≥ 6 months to <5 years: 10 mg/kg/dose PO/IV q12hrs ≥5 years: 10 mg/kg/dose PO/IV q24hrs Maximum daily dose: 750 mg | ALL AGES: CrCl 10-29 ml/min: 10mg/kg q24hrs CrCl <10 ml/min, HD/PD: 10mg/kg q48hrs |
| Linezolid | Adult 600 mg PO/IV q12h Pediatric 10 mg/kg PO/IV q8-12h | No adjustment necessary. Consider dose adjustment in CVVH (See dosing at end of this document) |
| Lopinavir/ritonavir (LPV/r) | Adult 400/100 mg PO q12h | No clear recommendations, but |

| Maraviroc | or 800/200 mg PO q24h (do not use once daily dosing in pts with >2 lopinavir resistance-associated substitutions, pregrancy, or patients receiving EFV, NVP, NFV, carbamazepine, phenobarbital, or phenytoin) Pediatric 10-13 mg (lopinavir component)/kg PO q12h 150 mg PO q12h: when used concomitantly | adjustment probably not necessary (<3% renal elimination). Avoid once daily dosing in patients receiving HD Caution in patients with hepatic |
|--|---|--|
| | with a potent CYP3A inhibitor (with or without a CYP3A inducer) including protease inhibitors (except tipranavir/ritonavir), delavirdine, ketoconazole, itraconazole, clarithromycin, nefazadone, and telithromycin 600 mg PO q12h: when used concomitantly with a potent CYP3A inducer (without a strong CYP3A inhibitor) including efavirenz, etravirine, rifampin, carbamazepine, phenobarbital, and phenytoin. 300 mg PO q12h: when used concomitantly with tipranavir/ritonavir, nevirapine, raltegravir, all nucleoside reverse transcriptase inhibitors, and enfuvirtide | impairment Caution in patients with CrCl<50 |
| Refer to dosing protocol on ASP website§ | Adult Standard dose: 500 mg IV q6h Simple urinary tract infection: 500 mg IV q8h see next page Meningitis, cystic fibrosis, meropenem MIC of 4 mcg/mL 2 g IV q8h Pediatric 20-40 mg/kg IV q8h (q12h for neonates 7 days old and under) | CrCl 25-49: 500 mg IV q8h CrCl 10-24: 500 mg IV q12h CrCl < 10: 500 mg IV q24h CrCl 25-49: 500 mg IV q12h CrCl 10-24: 250 mg IV q12h CrCl < 10: 500 mg IV q24h CrCl 25-49: 2 g IV q12h CrCl 10-24: 1 g IV q12h CrCl 10-24: 1 g IV q24h HD/CAPD: Dose as CrCl < 10 given after dialysis on dialysis days. CVVH: See dosing at end of this document |
| Metronidazole | Adult | after dialysis on dialysis days. Same for Adult & Pediatric |

| | 500 mg PO/IV q8h Pediatric 3.75-16.7 mg/kg PO/IV q6-8h (15-50 mg/kg/day) | CrCl <10, HD, or severe hepatic dysfunction: consider 50% at same interval if >14 day duration [∓] |
|------------------|---|---|
| Micafungin | Adult 50-150 mg IV q24h Pediatric 1-4.5 mg/kg IV q24h | No adjustment necessary. No clear recommendations. |
| Minocycline | Adult 100 mg PO q12h (200 mg PO qhs) Pediatric *not to be used in children < 8yo 2 mg/kg PO q12h (4 mg/kg PO qhs) | No adjustment necessary. |
| Moxifloxacin | Adult 400 mg PO/IV q24h Safety and efficacy not established in pediatrics. | No adjustment necessary. |
| Nelfinavir (NFV) | Adult 1250 mg PO q12h Pediatric 45-55 mg/kg PO q12h | No clear recommendations, but adjustment probably not necessary (<2% renal elimination). |
| Nevirapine (NVP) | Adult 200 mg PO q24h x14 days then increase to 200 mg PO q12h (immediate release tab) or 400 mg PO q24h (extended-release tab) Pediatric 4-7 mg/kg PO q12h | No adjustment necessary. Give dose after dialysis on dialysis days. Avoid if naïve and CD4 count > 250 cells/mm³ in women and 400 cells/mm³ in men |
| Nitrofurantoin | Adult 50-100 mg PO q12h Pediatric 1.25-1.75 mg/kg PO q6h | CrCl <50, HD/CAPD: Use is not recommended – will not reliably reach useful concentrations in urine and will have increased risk of toxicity |
| Oseltamivir | Adult 75 mg PO q12h Pediatric 30-75 mg PO q12h | Adult CrCl 30-60: 30 mg twice daily CrCl 10-30: 30 mg once daily ESRD on HD: 30 mg after HD session, treatment duration not to exceed 5 days ESRD on CAPD: single 30 mg dose administered immediately after a dialysis exchange |
| Oxacillin | Adult Methicillin-susceptible S. aureus bloodstream infections: 2g IV q4h Non-bloodstream infections 1-2g IV q4-6h | No adjustment necessary. |

| Tenicillin G Adult 250-500 mg PO q6-8h Penicillin VK Adult 250-500 mg PO q6-8h Penicillin VK Penicillin VK Adult 250-500 mg PO q6-8h Pentamidine Adult Adult Adult 250-500 mg PO q6-8h Pentamidine Adult A | | Dodietrie | 1 |
|--|---------------|----------------------------------|----------------------------------|
| Penicillin G | | Pediatric | |
| Penicillin G | | | |
| Pediatric Pedi | | | |
| ### after dialysis on dialysis days. CAPD: Dose as CrCl <10. | Penicillin G | | |
| Pediatric 25,000-100,000 units/kg IV q4-6h (100,000-400,000 units/kg/day) CrCl 10-30: same dose q8h (CrCl <10: same dose q12h | | | after dialysis on dialysis days. |
| Pediatric 25,000-100,000 units/kg IV q4-6h (100,000-400,000 units/kg/day) CrCl 10-30: same dose q8h (CrCl <10: same dose q12h | | | |
| 25,000-100,000 units/kg V q4-6h (100,000-400,000 units/kg V q4-6h (100,000-400,000 units/kg/day) CrCl <10: same dose q8h (rCl <10: same dose q12h | | Padiatric | |
| Adult 250-500 mg PO q6-8h No adjustment necessary. | | 25,000-100,000 units/kg IV q4-6h | |
| Pediatric G.25-16.7 mg/kg PO q6-8h HD: Give dose after dialysis on dialysis days. | | | after dialysis on dialysis days. |
| Pediatric G.25-16.7 mg/kg PO q6-8h (25-50 mg/kg/day) G.25-10 mg/kg/day) Pentamidine Adult 4 mg/kg IV q24h No adjustment necessary. | Penicillin VK | | |
| 6.25-16.7 mg/kg PO q6-8h (25-50 mg/kg/day) Pentamidine Adult 4 mg/kg IV q24h | | 250-500 mg PO q6-8h | No adjustment necessary. |
| Pediatric 4 mg/kg IV q24h Piperacillin Adult 3-4 g IV q4-6h Pediatric 33.3-75 mg/kg IV q4-6h Pediatric 33.3-75 mg/kg/day) Pediatric Amg/kg IV q4-6h Piperacillin No adjustment necessary. CrCl 10-30: same dose q36h CrCl <10: same dose q48h CrCl 10-50: same dose IV q6-8h CrCl <10: same dose IV q8h HD: Dose as CrCl <10. Give dose after dialysis on dialysis days. CAPD: Dose as CrCl <10. CrCl 20-40: same dose q8h CrCl <20: same dose q12h HD: Dose as CrCl <20. Give dose after dialysis on dialysis days. | | 6.25-16.7 mg/kg PO q6-8h | |
| 4 mg/kg IV q24h Piperacillin Adult 3-4 g IV q4-6h CrCl 10-50: same dose IV q6-8h CrCl <10: same dose IV q6-8h CrCl <10: same dose IV q8h HD: Dose as CrCl <10. Give dose after dialysis on dialysis days. CAPD: Dose as CrCl <10. Pediatric 33.3-75 mg/kg IV q4-6h (200-300 mg/kg/day) CrCl 20-40: same dose q8h CrCl <20: same dose q12h HD: Dose as CrCl <20. Give dose after dialysis on dialysis days. | Pentamidine | | No adjustment necessary. |
| Piperacillin Adult 3-4 g IV q4-6h CrCl 10-50: same dose IV q6-8h CrCl <10: same dose IV q8h HD: Dose as CrCl <10. Give dose after dialysis on dialysis days. CAPD: Dose as CrCl <10. Pediatric 33.3-75 mg/kg IV q4-6h (200-300 mg/kg/day) CrCl 20-40: same dose q8h CrCl <20: same dose q12h HD: Dose as CrCl <20. Give dose after dialysis on dialysis days. | | | |
| after dialysis on dialysis days. CAPD: Dose as CrCl <10. Pediatric 33.3-75 mg/kg IV q4-6h (200-300 mg/kg/day) CrCl 20-40: same dose q8h CrCl <20: same dose q12h HD: Dose as CrCl <20. Give dose after dialysis on dialysis days. | Piperacillin | | |
| Pediatric 33.3-75 mg/kg IV q4-6h (200-300 mg/kg/day) CrCl 20-40: same dose q8h CrCl <20: same dose q12h HD: Dose as CrCl <20. Give dose after dialysis on dialysis days. | | | after dialysis on dialysis days. |
| 33.3-75 mg/kg IV q4-6h (200-300 mg/kg/day) CrCl 20-40: same dose q8h CrCl <20: same dose q12h HD: Dose as CrCl <20. Give dose after dialysis on dialysis days. | | | |
| after dialysis on dialysis days. | | 33.3-75 mg/kg IV q4-6h | |
| · · · · · · · · · · · · · · · · · · · | | | after dialysis on dialysis days. |
| | | | |

| Piperacillin/tazobactam | Adult Extended 4hr infusion (standard at TNMC): | Extended 4hr infusion (standard |
|-------------------------------------|---|--|
| See dosing protocol on ASP website§ | 4.5 g IV q8h, infused over 4h | at TNMC): CrCl <20, HD/CAPD: 4.5 g IV q12h, infused over 4h CVVH: See dosing at end of this document |
| | Traditional, 30 minute infusion 3.375 g IV q6h or 4.5 g IV q8h | Traditional, 30 minute infusion CrCl 20-40: 2.25 g IV q6h CrCl <20: 2.25 g IV q8h |

| | A.C | 7 |
|---|--|---|
| | Anti-pseudomonal dosing: 4.5 g IV q6h | CrCl 20-40: 3.375 g IV q6h |
| | | CrCl <20: 2.25 g IV q6h |
| | | HD: Dose as CrCl <20 + 0.75 g IV after dialysis. CAPD: Dose as CrCl <20. |
| | Pediatric Extended infusion: >2kg and ≤40kg, over 40kg per adult dosing (all doses based on piperacillin component) 0-7 days: 100 mg/kg q12h, infused over 4h 8-28 days: 100 mg/kg q8h, infused over 4h >28 days: 100 mg/kg q6h, infused over 4h | CrCl 20-40: 70%, same interval [†] CrCl <20, HD/CAPD: 70%, infuse q12h over 4 hours [‡] |
| | NOTE: all doses must be infused over 4 hours, except in NICU patients Traditional, 30 minute infusion 50-133.3 mg/kg (piperacillin) IV q6-8h | CrCl 20-40: 70% IV q6h ^T CrCl <20: 70% IV q8h ^T |
| Posaconazole | [150-400mg/kg/day (piperacillin)] Adult & Pediatric (≥13 y.o.) | HD/CAPD: No recommendations |
| Restricted to review and | 200-800 mg PO q6-24h (q6h dosing preferred for active disease due to saturable absorption) | No adjustment necessary. |
| approval by the ID Service or the Hematology/Oncology Service | (Maximum 800 mg q24h) Take with high fat meal/nutritional supplement. Avoid concomitant use of proton-pump | Therapeutic drug monitoring suggested. Obtain steady state trough (7 days). Goal for active disease is >1.25 mg/L |
| | inhibitors & histamine receptor antagonists | 4100430 10 × 1.20 111g/L |
| Primaquine | Adult 15-30 mg (primaquine base) PO q24h Pediatric 0.3 mg/kg (primaquine base) PO q24h | No clear recommendations, but adjustment probably not necessary (<1% renal elimination). |
| Pyrazinamide | Adult | CrCl <10: 15 mg/kg PO q24h |
| | 25 mg/kg PO q24h (max dose 2gm PO for daily therapy) | HD: 25 mg/kg PO after each dialysis session. CAPD: No data. |
| | Pediatric 10-40 mg/kg PO q12-24h (max dose 2gm PO for daily therapy) | CrCl <10, HD: 40 mg/kg PO 3x/week |
| Dyrimothamina | (20-40 mg/kg/day) | CAPD: No data. |
| Pyrimethamine | Adult 50-100 mg PO q24h | No adjustment necessary. |
| | Pediatric 1 mg/kg PO q12h | |
| Quinupristin/dalfopristin | Adult & Pediatrics | No adjustment necessary. No data |
| Raltegravir (RAL) | 7.5 mg/kg IV q8h Adult and adolescent ≥16yrs | for pediatrics. |
| | 400mg PO q12H | No adjustment necessary. |

| | With rifampin: 800 mg PO q12h Pediatric Not established in <16yrs | |
|-------------------|---|---|
| Ribavirin | Adult 400-600 mg PO q12h Pediatric 200-400 mg PO q12h | Same for Adult & Pediatric CrCl <50: Contraindicated. |
| Rifabutin | Adult 300 mg PO q24h Pediatric 5 mg/kg PO q24h | No adjustment necessary. |
| Rifampin | Adult Mycobacterial disease: 10 mg/kg (600 mg) PO daily Prosthetic valve infective endocarditis: 300 mg PO/IV q8h Pediatric 10-20 mg/kg PO/IV q24h | No adjustment necessary. |
| Rilpivirine (RVP) | Adult: 25 mg daily Do not coadminister with H2RA, PPI, or antacids | No dose adjustment necessary |
| Rimantidine | Adult 100 mg PO q12h Pediatric 5 mg/kg PO q24h | CrCl <10: 100 mg PO q24h HD/CAPD: No data. No clear recommendations. |
| Ritonavir (RTV) | Adult 100 mg PO q12h (in combination with another protease inhibitor) 100 mg PO q24h when coadministered with atazanavir or daily darunavir Pediatric 400 mg/m² PO q12h | No adjustment necessary. |
| Saquinavir (SQV) | Adult 1000 mg PO q12h (w ritonavir 100 mg PO q12h) Not approved for use in pediatrics. | No data, but negligible renal clearance. |
| Stavudine (D4T) | Adult <60 kg: 30 mg PO q12h ≥60 kg: 40 mg PO q12h | CrCl 26-50: 50% PO q12h [‡] CrCl 10-25 and HD: 50% PO q24h [‡] Give after dialysis on dialysis days. CAPD: No data. |

| Pediatric 1 mg/kg PO q12h Adult 2-4 g PO in 3-6 divided doses Pediatric 37.5 mg/kg PO q6h Adult 300 mg PO q24h Pediatric 8 mg/kg PO q24h Adult 250-500 mg PO q6h | CrCl 25-50: 50% PO q12h [‡] CrCl <25: 50% PO q24h [‡] HD: Dose as CrCl <25. Give after dialysis on dialysis days. CAPD: No data. No data. Same for Adult & Pediatric CrCl 30-49: 300 mg q48h CrCl 10-29: 300 mg twice weekly CrCl <10: No data HD: 300 mg once weekly, given after dialysis if on a dialysis day. CAPD: No data. CrCl >50-90: same dose PO q8-12h |
|---|---|
| 2-4 g PO in 3-6 divided doses Pediatric 37.5 mg/kg PO q6h Adult 300 mg PO q24h Pediatric 8 mg/kg PO q24h Adult | dialysis on dialysis days. CAPD: No data. No data. Same for Adult & Pediatric CrCl 30-49: 300 mg q48h CrCl 10-29: 300 mg twice weekly CrCl <10: No data HD: 300 mg once weekly, given after dialysis if on a dialysis day. CAPD: No data. CrCl >50-90: same dose PO q8-12h |
| 2-4 g PO in 3-6 divided doses Pediatric 37.5 mg/kg PO q6h Adult 300 mg PO q24h Pediatric 8 mg/kg PO q24h Adult | Same for Adult & Pediatric CrCl 30-49: 300 mg q48h CrCl 10-29: 300 mg twice weekly CrCl <10: No data HD: 300 mg once weekly, given after dialysis if on a dialysis day. CAPD: No data. CrCl >50-90: same dose PO q8-12h |
| Adult 300 mg PO q24h Pediatric 8 mg/kg PO q24h Adult | CrCl 30-49: 300 mg q48h CrCl 10-29: 300 mg twice weekly CrCl <10: No data HD: 300 mg once weekly, given after dialysis if on a dialysis day. CAPD: No data. CrCl >50-90: same dose PO q8-12h |
| Adult | dialysis if on a dialysis day. CAPD: No data. CrCl >50-90: same dose PO q8-12h |
| | |
| | CrCl 10-50: same dose PO q12-24h CrCl <10: same dose PO q24h HD/CAPD: No data. |
| Pediatric *not to be used in children < 8yo 6.25-12.5 mg/kg PO q6h | CrCl 50-80: same dose q8h CrCl 10-49: same dose q12h CrCl <10: same dose q24h HD/CAPD: No data. |
| Adult 3 g IV q4h | CrCl 30-60: 2 g IV q4h CrCl 10-30: 2 g IV q8h CrCl <10: 2 g IV q12h |
| | HD: 2 g IV q12h with a 3 g IV supplement after each dialysis. CAPD: Dose as CrCl <10. |
| Pediatric 25-75 mg/kg IV q4-6h (150-300 mg/kg/day) | CrCl 10-30: same dose q8h CrCl <10: same dose q12h HD: Same dose 12h with dosing after dialysis. CAPD: Dose as CrCl <10. |
| Adult 100 mg IV load, then 50 mg IV q12h | Adults & Peds: Renal dysfunction: no adjustment necessary. |
| Pediatric Safety and efficacy not established in pediatrics. | Hepatic dysfunction, Child Pugh C: 100 mg IV load followed by 25 mg IV q12h |
| Adult 500 mg PO q12h (coadministered with ritonavir 200 mg PO q12h) Pediatric | No data, but negligible renal clearance. |
| | *not to be used in children < 8yo 6.25-12.5 mg/kg PO q6h Adult 3 g IV q4h Pediatric 25-75 mg/kg IV q4-6h (150-300 mg/kg/day) Adult 100 mg IV load, then 50 mg IV q12h Pediatric Safety and efficacy not established in pediatrics. Adult 500 mg PO q12h (coadministered with ritonavir 200 mg PO q12h) |

| | pediatrics. | |
|---|--|---|
| Tobramycin | Adult & Pediatric Extended interval dosing (most indications*): 7 mg/kg once daily adjusted by serum level 6-14 hrs after start of infusion and Hartford nomogram (see PK training packet on ASP website [§]) 5 mg/kg/day may be used for UTIs | Extended interval dosing frequency determined by levels/Hartford nomogram |
| | 2 | |
| | Traditional dosing 1.5-2.5 mg/kg IV q8h | Traditional dosing (empiric, before levels): |
| | Monitoring of serum levels is recommended. *Refer to TNMC PK training packet on ASP website§ for exclusions to extended-interval | CrCl 51-90: 60-90% IV q8-12h [‡] CrCl 10-50: 30-70% IV q12h [‡] CrCl <10: 20-30% IV q24-48h [‡] |
| | dosing. Pediatric | HD/CAPD: Dose according to levels. CVVH: See dosing at end of this document |
| Tring of the province for 15 and 11 and 1 | Traditional dosing 1.5-2.5 mg/kg IV q8h | Adulta and Dadiatrics DO/D/ |
| Trimethoprim/sulfamethoxazole (TMP/SMX) | Adult PO | Adults and Pediatrics, PO/IV |
| 1 Bactrim DS tablet = 160mg(TMP)/800mg(SMX) | Simple urinary tract infection: 1 Bactrim DS tablet PO q12h Skin/skin structure infection/other infections: | Simple UTI, skin/skin structure, other infections CrCl <30: 50% of usual daily dose divided q12-24h |
| Bactrim oral suspension = 40mg/5 mL (TMP)/ 200mg/5 mL (SMX) | 1-2 Bactrim DS tablets PO q12h PCP treatment:15-20 mg/kg/day* (trimethoprim componenent) PO divided q6-8h | HD: Dose as CrCl<30, administer after HD on HD days |
| | IV Skin/skin structure infection: 10 mg/kg/day (ideal body weight) trimethoprim component divided q12h | PCP treatment: CrCl 15-30: 15-20 mg/kg/day (trimethoprim component) q6-8h for 48 hours followed by 50% of usual daily dose divided q12h |
| | Severe Infections/PCP 15-20 mg/kg/day* (trimethoprim component) IV divided q6-8h *Ideal body weight, consider an adjusted body | CrCl <15: 50% of usual daily dose divided q12h HD: Dose as CrCl<15, administer after HD on HD days |
| | weight in severely ill obese patients. See equation for adjusted body weight at end of document | |
| | Pediatric PO/IV Simple urinary tract infection" 5 mg/kg (TMP) PO q12h | |
| | Skin/skin structure infection/other infections: 10 mg/kg/day (TMP) IV divided q12h | |

| | PCP treatment: | |
|----------------|---|---|
| | 15-20 mg/kg/day (TMP) IV divided q6-8h | |
| Valacyclovir | Adult 2 g PO q12h | CrCl 30-49: 1 g PO q12h CrCl 10-29: 500 mg PO q12h CrCl <10: 500 mg PO q24h |
| | 1 g PO q8h | CrCl 30-49: 1 g PO q12h CrCl 10-29: 1 g PO q24h CrCl <10: 500 mg PO q24h |
| | 1 g PO q12h | CrCl 30-49: no adjustment CrCl 10-29: 1 g PO q24h CrCl <10: 500 mg PO q24h |
| | 1 g PO q24h | CrCl 30-49: no adjustment CrCl 10-29: 500 mg PO q24h CrCl <10: 500 mg PO q24h |
| | 500 mg PO q12h | CrCl 30-49: no adjustment CrCl 10-29: 500 mg PO q24h CrCl <10: 500 mg PO q24h |
| | 500 mg PO q24h | CrCl 30-49: no adjustment CrCl 10-29: 500 mg PO q48h CrCl <10: 500 mg PO 48h |
| | Safety and efficacy not established in pediatrics. | HD: Dose as CrCl <10. Give after dialysis on dialysis days. CAPD: 500 mg PO q48h |
| Valganciclovir | Adult Treatment, induction 900 mg PO q12h | Adult Treatment, induction CrCl 40-59: 50% PO same interval [†] CrCl 25-39: 50% PO q24h [‡] CrCl 10-24: 50% PO q48h [‡] CrCl <10, HD/CAPD: Use is not recommended. |
| | Treatment, maintenance 900 mg PO q24h | Treatment, maintenance CrCl 40-59: 50% PO same interval [†] CrCl 25-39: 50% PO q48h [‡] CrCl 10-24: 50% PO twice weekly [‡] CrCl <10, HD/CAPD: Use is not recommended. |
| | Prophylaxis (dosing at TNMC) 450 mg PO q24h | Prophylaxis CrCl 25-39: same dose PO q48h [‡] CrCl 10-24: 450 mg PO twice weekly [‡] CrCl <10, HD/CAPD: Use is not recommended. |
| | Pediatric (Usual dosing at TNMC) Treatment 14 mg/kg PO q12h | Pediatric Treatment CrCl 40-59: 50% PO same interval [†] CrCl 25-39: 50% PO q24h [‡] CrCl 10-24: 50% PO q48h [‡] |

| | | CrCl <10, HD/CAPD: Use is not recommended. |
|------------------|--|---|
| | Maintenance or Prophylaxis 14 mg/kg PO daily | Maintenance or Prophylaxis CrCl 40-59: 50% PO same interval [†] CrCl 25-39: 50% PO q48h [‡] CrCl 10-24: 50% PO twice weekly [‡] CrCl <10, HD/CAPD: Use is not recommended. |
| Vancomycin IV | Adult Standard*: 15-20 mg/kg IV q12h Consider 25 mg/kg x1 loading dose in critically ill patients | *Dosing, therapeutic goals, and monitoring should be individualized for each patient; consult pharmacy. Refer to PK training packet on ASP website§ |
| | | Troughs of 15-20 mcg/mL are recommended for patients with MRSA bloodstream infections, endocarditis, meningitis, pneumonia, osteomyelitis, and septic arthritis. |
| | | CVVH: See dosing at end of this document |
| | Pediatric 15-20 mg/kg IV q6h* | CrCl 70-89: same dose q8h CrCl 46-69: same dose q12h CrCl 30-45: same dose q18h CrCl 15-29: same dose q24h CrCl <15, HD/CAPD: Measure trough levels to determine when to dose. |
| Vancomycin PO | 125 mg PO q6h | No renal adjustment necessary |
| Voriconazole | Adult & Pediatric (>12 yo)* PO/IV Active disease: Loading dose of 6mg/kg PO/IV q12h x2doses, then 4 mg/kg PO/IV q12h Prophylaxis: 200 mg PO q12h (100 mg q12h if <40kg) | Hepatic dysfunction (Child Pugh A or B): 6mg/kg q12h x2doses then 50% of normal daily dose. Renal dysfunction: PO No adjustment necessary. |
| | Therapeutic drug monitoring is suggested. Voriconazole target trough at steady-state is 2 - 5.5 mg/L. | IV CrCl <50, HD/CAPD: Caution with IV formulation due to accumulation of cyclodextrin vehicle. |
| Zanamivir IH | Adult and Pediatric ≥7 years Treatment: Two inhalations (10 mg total) twice daily for 5 days Adult and Pediatric ≥5 years Prophylaxis: Two inhalations (10 mg total) once daily for daily for 10 days | No adjustment necessary. |
| Zidovudine (AZT) | Adult PO: 300 mg PO q12h | CrCl <15, HD/CAPD: 100 mg PO q6- 8h. Give after dialysis on dialysis |
| | IV for intrapartum administration: | days. |

| 2 mg per kg body weight intravenously over 1 hour, followed by continuous infusion of 1 mg per kg body weight per hour. Refer to DHHS guidelines for dosage and duration for continuation post-partum | CrCl <15, HD/CAPD: 1 mg/kg IV q6-8h. Give after dialysis on dialysis days. |
|---|--|
| Pediatric PO: 160 mg/m ² PO q8h IV: 120 mg/m ² IV q6h | No data. |

^{*}use Cockroft-Gault equation for patients ≥ 18 years old; use Schwartz method for patients < 18 years old

Adults: Estimate of Creatinine Clearance using Cockroft-Gault equation

CrCl (ml/min) =
$$\frac{(140 - age) * IBW}{72 * Scr}$$
 x 0.85(for females only)

Scr = serum creatinine concentration in mg/dL; if patient is > 65 years old and Scr < 1 mg/dL, round up to 1.0

IBW = ideal body weight

IBW (males) = 50 + (2.3 x inches > 5 feet)

IBW (females) = 45.5 + (2.3 x inches > 5 feet)

NOTE: use actual body weight if less than ideal body weight

Adjusted body weight: ideal body weight + 0.4(actual body weight - ideal body weight)

Pediatrics: Estimate of Creatinine Clearance using Schwartz's equation

CrCl (ml/min) = K x L/Scr

K = Constant of proportionality that is age specific

| <u>Age</u> | K |
|--------------------------------|--------------|
| Preterm infants up to 1 year | 0.33 |
| Full-term infants up to 1 year | 0.45 |
| 1-12 years | 0.55 |
| 13-17 years female | 0.55 |
| 13-17 years male | 0.7 |
| 1-12 years | 0.55 0.55 |

L = length or height in cm

Scr = serum creatinine concentration in mg/dL

Selected References, General Renal Dose Adjustments

- 1. Gilbert DN, et al. The Sanford Guide to Antimicrobial Therapy, 38th Edition, 2008.
- 2. MICROMEDEX® Healthcare Series, 2012.
- 3. Livornese LL, et al. Use of antibacterial agents in renal failure. *Infectious Disease Clinics of North America*. 2004;18:551-79.
- 4. Taketomo CK, et al. *Pediatric Dosage Handbook*, 12th Edition, 2005.
- 5. Aronoff GR, et al. *Drug Prescribing in Renal Failure*, 4th Edition, 1999.

When the recommended renal dosage adjustment is listed as a percentage change, this indicates that X% of the originally ordered dose should be given, NOT that the dose should be decreased by X%. For example, an adult with a CrCl between 10-50 ml/min would receive 30-70% of the originally ordered amikacin dose

[§]Antimicrobial stewardship program (ASP) website: www.nebraskamed.com/asp

Anti-infective dosing recommendations in continuous venovenous hemofiltration (CVVH) at The Nebraska Medical Center

Please note:

- -In patients with renal failure, the time to achievement of steady-state is increased for renally-eliminated agents. In addition, patients on CRRT frequently have an increased volume of distribution for many agents. Therefore, a loading dose should be utilized if not initiating therapy at the full dose.
- -Patients undergoing CVVH are at a high risk of being underdosed. For agents with relatively large therapeutic windows (e.g. beta-lactams) being used in critically ill patients, erring on the side of aggressive dosing may be prudent.
- -Monitor patients for interruption of CVVH (e.g. clotting) or changing filtration rates. When CVVH is off, dose as hemodialysis patients or based on any residual renal function.

| Drug | Loading dose for | Standard anephric dose | Dose by CVVH flow rate | | | |
|--------------------------------|---------------------|--|--|-----------------|--------------------|-----------------|
| - | CRRT | | 1 L/h | 2 L/h | 3 L/h | 4 L/h |
| Aminoglycosides ¹ | 3 mg/kg gent/tobra; | Provide loading dose then dose per | Provide loading dose then dose per therapeutic drug monitoring; patients may | | | |
| | 10 mg/kg amikacin | therapeutic drug monitoring | require repeat dosing q24h at flow rates >1 L/h | | | |
| Acyclovir# ¹ | NA | 2.5-5 mg/kg q24h | 5-7.5 mg/kg q24h | 5-10 mg/kg q24h | 5-10 mg/kg q24h | 5-10 mg/kg q24h |
| Aztreonam ² | 2 g | 1-2 g q24h | 1 g q8h | 2g q12h | 2 g q8h | 2 g q6h |
| Cefazolin ² | 2 g | 1 g q24h | 1 g q12h | 1 g q12h | 1 g q8h | 1 g q8h |
| Cefepime ¹ | 2 g | 1 g q24h | 1 g q12-24h | 1 g q12h | 1 g q8h | 1 g q6h |
| Ceftazidime ² | 2 g | 1 g q24h | 1 g q12h | 2g q12h | 2 g q8h | 2 g q8h |
| Ceftriaxone ^{3,4} | NA | 1-2 g q12-24h | No adjustment necessary; dose as anephric | | | |
| Ciprofloxacin ¹ | NA | 400 mg (IV) or 500 mg (PO) q24h | No adjustment necessary; dose as anephric | | | |
| Daptomycin ¹ | NA | 6 mg/kg q48h | No adjustment necessary; dose as anephric | | | |
| Fluconazole*1,5 | 800 mg (12mg/kg) | 400 mg (6 mg/kg) post dialysis sessions* | 200 mg q24h | 400 mg q24h | 400 mg q12h | 400 mg q12h |
| Levofloxacin ^{3,7} | 500-750 mg | 250 mg q24h | 250 mg q24h or | 250 mg q24h or | 250 mg q24h or | 500 mg q24h |
| | | | 500 mg q48h | 500 mg q48h | 500 mg q48h | |
| Linezolid ^{1,6} | NA | 600 mg q12h | 600 mg q12h | 600 mg q12h | 600 mg q8-12h | 600 mg q8-12h |
| Meropenem ^{1,3} | 1-2 g | 500 mg q24h | 500 mg q12h | 500 mg q8h | 500 mg q6h | 500 mg q6h |
| Moxifloxacin | NA | 400 mg q24h | No adjustment necessary | | | |
| Oxacillin | NA | 2 g q4h | No adjustment necessary | | | |
| Piperacillin/ tazobactam EI | NA | 4.5 g (administered over 4h) q12h | 4.5 g EI q12h | 4.5 g EI q8h | 4.5 g EI q8h | 4.5 g EI q8h |
| Vancomycin ³ | 20-25 mg/kg | Provide loading dose then dose per | Provide loading dose then per therapeutic drug monitoring; patients may | | | |
| | | therapeutic drug monitoring; | require approximately 500 mg q12h at flow rates >1 L/h | | | |

#Use lower dose for mucocutaneous HSV and higher dose for HSV encephalitis or VZV; *Dose assuming invasive candidiasis; EI, 4-hour extended-infusion; NA, Not applicable

References, CVVH dosing:

- 1. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009 May;29(5):562-77.
- 2. Scheetz MH, Scarsi KK, Ghossein C, Hurt KM, Zembower TR, Postelnick MJ. Adjustment of antimicrobial dosages for continuous venovenous hemofiltration based on patient-specific information. Clin Infect Dis. 2006 Feb 1;42(3):436-7
- 3. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007;46(12):997-1038.
- 4. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy. 2000 Jun;20(6):635-43.
- 5. Bergner R, Hoffmann M, Riedel KD, Mikus G, Henrich DM, Haefeli WE, Uppenkamp M, Walter-Sack I. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant. 2006 Apr;21(4):1019-23. Epub 2005 Nov 25.
- 6. Meyer B, Kornek GV, Nikfardjam M, Karth GD, Heinz G, Locker GJ, Jaeger W, Thalhammer F. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother. 2005 Jul;56(1):172-9. Epub 2005 May 19.
- 7. Trotman RL, Williamson JC, Shoemaker, DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005; 41:1159-66.

Dates Reviewed:

Antimicrobial Stewardship Program draft – October 2005, September 2008, January 2012 Medical Staff Pharmacy & Therapeutics Committee approved – April 2006, September 2008, October 2010, March 2012

Medical Staff Executive Committee approved – May 2006

Updated March 2014